



Advertisement

Trending Stories



Brain health: how can you reduce cognitive decline? An interview with Heather Snyder,



CHOP scientist says that mitochondria play central role in human evolution, disease



Cattle virus found in human cancer cells



Sleeping in lateral position may effectively remove brain waste, say Stony Brook researchers



EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at



Better treatment could be on the horizon for Myasthenia Gravis

Study: Increased acetylation of histones promotes fear extinction in mice

Published on September 29, 2015 at 6:22 AM · No Comments

Recommend Share

The targeted modulation of gene activity and cellular signaling pathways could provide a new approach to the treatment of fear and anxiety states according to the recent findings of a project sponsored by the Austrian Science Fund FWF.

Fear extinction is a classical method used in anxiety therapy: memories of negative – anxiety-producing – experiences can be "overwritten" by new learning involving positive (safe) associations. If you have ever been bitten by a dog, you are bound to be afraid of dogs. But if you subsequently have repeated encounters with dogs with no ill effects, the fear will fade. As simple as this method sounds and as effective as it may be, it does not work equally well for everyone. In an FWF project entitled "Epigenetic Mechanisms of Disturbed Memory Regulation" within the Special Research Programme (SFB) of "Cell Signaling in Chronic CNS Disorders", Nicolas Singewald set out to find out why that is so and how extinction can be boosted.

ACETYLATION COUNTERING ANXIETY

Singewald's team focussed specifically on epigenetic effects, i.e. changes in the genome that are acquired in the course of life. Specifically, the team investigated a chemical change (acetylation) of certain DNA-associated proteins (histones) that are believed to have a positive influence on fear extinction. The team succeeded in showing that such chemical modifications can augment and correct impaired fear extinction. Together with SFB and international colleagues, they also identified key cellular mechanisms underlying this effect.

SCAREDY CATS AMONG THE MICE

Singewald's team used a special mouse strain (129S1/SvImJ) which they had previously identified together with the US brain researcher Andrew Holmes. Like anxiety patients, these mice exhibit a reduced capacity for fear extinction and are therefore an ideal model for identifying cellular and molecular mechanisms that can promote anxiety therapy. In fact, the researchers found that increased acetylation of histones promotes fear extinction in these mice, thus establishing a clear relationship between epigenetic modifications and the correction of impaired extinction. In further convincing experiments, the group then identified cellular and molecular processes that contribute to this mechanism.

ORPHAN RECEPTORS

The team showed that, following histone acetylation, specific genes are recruited for fear extinction. "In fact, we revealed that for fixing of impaired extinction the involvement of certain genes and their gene products known to influence the plasticity of nerve endings, or synapses is important. We also discovered a number of genes for hitherto unknown receptors to play a role. The search for compounds that could interact with these receptors is now ongoing," says Singewald, explaining the results. Other molecular players suspected of influencing fear extinction were discovered in further studies, namely specific RNAs. These molecules are usually responsible for translating the genetic code into protein structures. However, it has long been known that some RNAs have other functions as well. It was precisely such RNAs (ncRNAs and miRNAs) that Singewald and his cooperation partners within the SFB found to be involved in facilitating fear extinction.

THERAPEUTIC CONCEPT


The team found that receptors activated by classical neurotransmitters such as dopamine are also involved and formulated an approach to treating impaired extinction that may be beneficial in humans. "To investigate this therapeutic concept, we took advantage of the fact that an approved drug (for Parkinson's disease) exists that has an activating effect

Related Stories

- **People with specific genotype are more deeply affected by life experiences, reveals study**
- **CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel**
- **New collaboration may allow researchers to develop potential gene therapies for pediatric diseases**

Wir eröffnen
Ihrem
Unternehmen
neue Chancen.


Nr. 1 in CEE*
plus weltweites
Netzwerk inkl. USA
und Asien!



Jetzt informieren >

Rechtshinweis

Bank Austria
Member of UniCredit
Advertisement



Shop now →

Advertisement

Latest News



Vanderbilt researchers study novel sound wave technology to diagnose sports concussions



Phase II IMvigor 210 data shows atezolizumab may prevent progression of



Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting



OJ-Bio to showcase new smartphone-enabled diagnostic testing device at Medica 2015



Polio no more in Nigeria, WHO says



European survey sheds light on decision-making criteria of physicians treating advanced



News Medical
208,641 likes

Like Page

Share

Be the first of your friends to like this



News Medical



Follow

+1

+ 3,996

on dopamine-dependent signaling pathways," Singewald says. Together with international colleagues, the team obtained convincing results. "We were able to show in both mice as well as in healthy humans that this therapeutic concept had sustained fear-inhibiting effects," Singewald reports.

The results of the FWF project indicate that the augmentation of certain cellular and (epi)genetic processes could offer new approaches to the treatment of fear and anxiety. This could provide hope for more effective treatment of pathological fear in the future for individuals in whom treatment concepts based on fear extinction, e.g. exposure therapy, do not work optimally.

Source:

<http://www.uibk.ac.at/>

Be the first to rate this post

Posted in: [Medical Science News](#) | [Medical Research News](#) | [Medical Condition News](#)

Tags: [Acetylation](#), [Anxiety](#), [Brain](#), [Cell](#), [DNA](#), [Dopamine](#), [Gene](#), [Genes](#), [Genetic](#), [Parkinson's Disease](#), [Protein](#)

[Permalink](#) | [Comments \(0\)](#)

XING

Jobs, die zum Leben passen. Über 65.000 Jobs in Österreich!



Advertisement


Prior News

Research posters support utility of EKF's PointMan DNA enrichment technology for rapid detection of lung cancer mutations

Next News

New tools to measure S-Adenosylmethionine (SAM) and methylation index


Suggested Reading



Scientists identify a gene that can cause more aggressive cancer in AML patients



New study heightens concerns over detrimental impact of air pollution on gene associated with



Quethera receives seed investment funding to develop gene therapy for glaucoma



Matchmaker Exchange platform launched for uncovering rare disease genes




Bionomics' BNC210 Phase 1 trial for anxiety and depression meets primary endpoint



Researchers find mutated gene responsible for cardiac angiosarcoma in two



Satellite DNA plays vital regulatory role in how organisms adapt to environmental



University of Adelaide study sheds light on the activity of cancer-suppressing gene

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



Post a new comment

Login

Quirky Comment Title (optional)

Text area for writing a comment.

Post